Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 219-143-7 | CAS number: 2372-21-6
Endpoint summary
Administrative data
Link to relevant study record(s)
- Endpoint:
- basic toxicokinetics, other
- Adequacy of study:
- weight of evidence
- Executive summary:
Detailed absorption, metabolism, distribution and elimination data are not available for CAS # 2372-21-6. Available phys-chem characteristics, in vitro studies, and some animal studies provide some useful information to understand the toxicokinetics of this substance. Based on these, the oral and dermal absorption does take place with some biological effects as described. No information on metabolism and elimination are available.
Reference
Description of key information
Detailed absorption, metabolism, distribution and elimination data are not available for this substance. Available phys-chem characteristics, in vitro studies, and some animal studies provide may be useful information to understand the toxicokinetics of this substance.
In a repeated dose oral gavage study in rats (OECD 422), some microscopic effects in male rat kidneys (hyaline droplets) were noted showing that the substance was absorbed form the GI track and distributed in the body. The effects were due to either the parent substance or its metabolite(s). The oral absorption rate was considered 100%.
Dermal absorption of the substance was confirmed from the skin sensitization study in the guinea pigs (a positive immune system effect which is a systemic response) and skin irritation studies in rabbits. Again the extent of absorption and metabolism are unknown. The phys-chemical properties support skin penetration to some degree. The dermal absorption rate was assumed to be 50%.
Since the vapor pressure of the substance is low, inhalation is not expected to to be the major route of exposure. No animal data are available either. Based on phys-chem properties, any absorption of deposited material in the mucus (of the respiratory system) is expected to be similar to that of the GI track, i.e., 100%.
Based on these, there is evidence that oral and dermal absorption and distribution does take place with some biological effects as described. No information on metabolism and elimination are available.
Key value for chemical safety assessment
- Bioaccumulation potential:
- no bioaccumulation potential
- Absorption rate - oral (%):
- 100
- Absorption rate - dermal (%):
- 50
- Absorption rate - inhalation (%):
- 100
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
